{
    "nctId": "NCT06405295",
    "briefTitle": "A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation",
    "officialTitle": "A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "iDFS%",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG score 0-1\n* TNBC\n* BRCA1/2 mutation\n* No distant metastases assessed by imaging after surgical treatment\n* Breast cancer that is non-pCR after neoadjuvant therapy, or postoperative pathology suggestive of \u2265pT2, or \u2265pN1\n* Have completed postoperative adjuvant chemotherapy and/or radiotherapy\n* No major organ dysfunction\n\nExclusion Criteria:\n\n* Patients who are unable to take oral medication, or who refuse this medication regimen\n* Already enrolled in another study, or less than or equal to 4 weeks from discontinuation of another medication\n* Presence of severe dysfunction of vital organs\n* Patients with other malignancies (with the exception of cured non-melanoma skin cancers, carcinoma in situ of the cervix and other tumours that have been cured for at least 5 years)\n* Acute infectious disease or active chronic infectious disease\n* History of uncontrolled epilepsy, central nervous system disease or mental disorder",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}